Theodore Dickens, Shiffman Mitchell L, Sterling Richard K, Bruno Christine J, Weinstein Jeffrey, Crippin Jeffrey S, Garcia Gabriel, Wright Teresa L, Conjeevaram Hari, Reddy Rajender K, Nolte Frederick S, Fried Michael W
University of North Carolina at Chapel Hill, North Carolina 27599, USA.
Dig Dis Sci. 2003 Jan;48(1):140-5. doi: 10.1023/a:1021750818611.
To determine if an intensive regimen of daily, high-dose interferon would improve the initial response rates to therapy for hepatitis C genotype 1 among African American and Caucasian patients, we conducted a retrospective analysis of a treatment trial conducted between October 1995 and June 1997. Patients were randomized to 24 weeks of therapy with interferon--alpha-2b at either 5 MU daily or 3 MU three times a week. On the standard interferon regimen (3 MU three times a week) African Americans and Caucasians had similar initial response rates. However, unlike Caucasians, African Americans did not have an increased initial virological response when treated with an intensive, daily dose regimen. Levels of HCV RNA decreased more slowly during the first 12 weeks of therapy among African Americans. Nelson-Aalen cumulative hazard estimates for the different race and dose combinations revealed that Caucasians who received daily interferon were most likely to have an initial response (logrank, P < 0.001).
为了确定每日高剂量干扰素强化治疗方案是否会提高非裔美国人和白种人患者中丙型肝炎1型的初始治疗反应率，我们对1995年10月至1997年6月期间进行的一项治疗试验进行了回顾性分析。患者被随机分配接受24周的干扰素-α-2b治疗，剂量为每日5 MU或每周三次3 MU。在标准干扰素治疗方案（每周三次3 MU）下，非裔美国人和白种人的初始反应率相似。然而，与白种人不同，非裔美国人在接受强化每日剂量治疗时，初始病毒学反应并未增加。在治疗的前12周内，非裔美国人的HCV RNA水平下降得更慢。不同种族和剂量组合的纳尔逊-阿alen累积风险估计显示，接受每日干扰素治疗的白种人最有可能出现初始反应（对数秩检验，P < 0.001）。
